NEW YORK, NY / ACCESSWIRE / July 11, 2022 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Okta, Inc. (NASDAQ:OKTA)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/okta-inc-loss-submission-form?prid=29721&wire=1
Lead Plaintiff Deadline: July 19, 2022
Class Period: March 5, 2021 – March 22, 2022
Allegations against OKTA include that: (i) Okta had inadequate cybersecurity controls; (ii) as a result, Okta’s systems were vulnerable to data breaches; (iii) Okta ultimately did experience a data breach caused by a hacking group, which potentially affected hundreds of Okta customers; (iv) Okta initially did not disclose and subsequently downplayed the severity of the data breach; (v) all the foregoing, once revealed, was likely to have a material negative impact on Okta’s business, financial condition, and reputation; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Spero Therapeutics, Inc. (NASDAQ:SPRO)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/spero-therapeutics-inc-loss-submission-form?prid=29721&wire=1
Lead Plaintiff Deadline: July 25, 2022
Class Period: October 28, 2021 – May 2, 2022
Allegations against SPRO include that: (i) the data submitted in support of the New Drug Application (“NDA”) for the Company’s product candidate, Tebipenem HBr, were insufficient to obtain approval from the U.S. Food and Drug Administration (“FDA”); (ii) accordingly, it was unlikely that the FDA would approve the Tebipenem HBr NDA in its current form; (iii) the foregoing would necessitate a significant workforce reduction and restructuring of Spero’s operations; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/verrica-pharmaceuticals-inc-loss-submission-form?prid=29721&wire=1
Lead Plaintiff Deadline: August 5, 2022
Class Period: May 28, 2021 – May 24, 2022
Allegations against VRCA include that: (1) there were manufacturing deficiencies at the facility where Verrica’s contract manufacturer produced a bulk solution for the Company’s lead product candidate, VP-102; (2) these deficiencies were not remediated when Verrica resubmitted its New Drug Application for VP-12 for molluscum; (3) the foregoing presented significant risks to Verrica obtaining regulatory approval of VP-102 for molluscum; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com:
https://www.accesswire.com/708233/SHAREHOLDER-ALERT-OKTA-SPRO-VRCA-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines
